Companies / Information Technology
ACN
Accenture
IT Consulting & Other Services
IT Consulting & Other ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health70
Growth44
Profitability49
Cash generation81
Balance sheet86
Dilution control90
Key ratios and five-year financials
Latest quarter revenue YoY (2026-08-31)6.2%Revenue growth (FY)6.5%Revenue CAGR (3y)5.0%Gross margin32.0%Operating margin15.4%Net margin11.3%Free cash flow margin15.7%R&D / revenue1.4%Stock comp / revenue2.8%Net debt / operating cash flow-0.22xCurrent ratio1.43Diluted share count change-2.4%
| Fiscal year ending | FY 2022-08 | FY 2023-08 | FY 2024-08 | FY 2025-08 | FY 2026-08 |
|---|---|---|---|---|---|
| Revenue | $61.6B | $64.1B | $64.9B | $69.7B | $74.2B |
| Gross profit | $19.7B | $20.7B | $21.2B | $22.2B | $23.8B |
| Operating income | $9.4B | $8.8B | $9.6B | $10.2B | $11.4B |
| Net income | $6.9B | $6.9B | $7.3B | $7.7B | $8.4B |
| Operating cash flow | $9.5B | $9.5B | $9.1B | $11.5B | $12.4B |
| Capital expenditure | $718M | $528M | $517M | $600M | $743M |
| Free cash flow | $8.8B | $9.0B | $8.6B | $10.9B | $11.6B |
| R&D | $1.1B | $1.3B | $1.2B | $817M | $1.0B |
| Stock-based comp | $1.7B | $1.9B | $1.9B | $2.1B | $2.1B |
| Buybacks | $4.1B | $4.3B | $4.5B | $4.6B | $7.5B |
| Dividends | $2.5B | — | — | — | — |
| Cash | $7.9B | $9.0B | $5.0B | $11.5B | $12.8B |
| Total debt | $46M | $43M | $1.0B | $5.1B | $10.1B |
| Equity | $22.1B | $25.7B | $28.3B | $31.2B | $31.6B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.